FACULTY
Mehdi Hamadani, MD
Chief of Hematologic Malignancies
Endowed Professor and Associate Director of Clinical Research
Medical College of Wisconsin
Milwaukee, Wisconsin
PROGRAM OVERVIEW
This CME activity will provide hematologists and oncologists with practical, case-based insights into the management of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, with a special focus on follicular lymphoma (R/R FL). Expert faculty will review prognostic tools and clinical features, including early relapse, to guide risk stratification and inform treatment planning. The program will highlight the role of bispecific antibody therapies, with an emphasis on integrating clinical trial data into personalized care strategies. Special attention will be given to proactive recognition, grading, and management of toxicities, particularly cytokine release syndrome, as well as best practices in infection prophylaxis and monitoring. Through didactic discussion, illustrative case study, and whiteboard animation, learners will gain strategies to optimize outcomes and safely implement bispecific therapies for patients with R/R FL.
TARGET AUDIENCE
This activity is designed to meet the educational needs of clinicians involved in the evaluation and management of patients with MM and B-NHLs including, but not limited to, hematologists, hematologist/oncologists, oncologists, general physicians (GPs), and advanced practice providers (APPs; eg, nurse practitioners, oncology nurses, pharmacists, and physician assistants).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the constellation of clinical presentation features warranting further B-NHL evaluation and specialist referrals
- Utilize current and emerging clinical trial data for bispecific antibodies to inform the development of personalized treatment plans for patients with R/R B-NHLs
- Develop proactive AE mitigation, identification, and management plans for patients with R/R B-NHLs receiving treatment with a bispecific antibody
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.75 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty | Relationship | Manufacturer |
| Mehdi Hamadani, MD | Consultant Speakers bureau Contracted research |
AlloVir, Autolus Therapeutics, Byondis, Caribou Biosciences, CRISPR Therapeutics, Daiichi Sankyo, Forte Biosciences, Genmab, and Kite Pharma ADC Therapeutics, AstraZeneca, BeiGene, Kite Pharma, and Sobi ADC Therapeutics, Astellas Pharma, and Spectrum Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Lauren Scott, MD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Dominique Barton, BS, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, MM, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to the enduring event at [email protected]
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
